Treatment outcomes of multi drug resistant and rifampicin resistant Tuberculosis in Zimbabwe: A cohort analysis of patients initiated on treatment during 2010 to 2015

BACKGROUND: Zimbabwe is one of the thirty countries globally with a high burden of multidrug-resistant tuberculosis (TB) or rifampicin-resistant TB (MDR/RR-TB). Since 2010, patients diagnosed with MDR/RR-TB are being treated with 20–24 months of standardized second-line drugs (SLDs). The profile, ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Matambo, Ronnie, Takarinda, Kudakwashe C., Thekkur, Pruthu, Sandy, Charles, Mharakurwa, Sungano, Makoni, Talent, Ncube, Ronald, Charambira, Kelvin, Zishiri, Christopher, Ngwenya, Mkhokheli, Nyathi, Saziso, Chiteka, Albert, Chikaka, Elliot, Mutero-Munyati, Shungu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192497/
https://www.ncbi.nlm.nih.gov/pubmed/32353043
http://dx.doi.org/10.1371/journal.pone.0230848

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192497/
https://www.ncbi.nlm.nih.gov/pubmed/32353043
http://dx.doi.org/10.1371/journal.pone.0230848

Ejemplares similares